GlassScriptPhysician profile
Stephanie A Williams
NPI 1568816098
$4,709.43
in general payments reported to CMS, 2019-2025
38 companies · $773 in 2025
The $773 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $184 · 2022: $1,305 · 2023: $1,497 · 2024: $952 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,221.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $645.89 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $391.34 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $390.02 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $291.56 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Phathom Pharmaceuticals, INC. | $249.30 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $239.36 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $232.06 | 2023-2025 | Rexulti, Nuedexta |
| E.R. Squibb & Sons, L.L.C. | $203.52 | 2024 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $196.55 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $193.17 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Bayer Healthcare Pharmaceuticals INC. | $182.25 | 2022-2023 | |
| Gilead Sciences, INC. | $174.33 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $116.95 | 2023 | Jornay Pm |
| Alkermes, INC. | $112.22 | 2023 | Lybalvi |
| Galderma Laboratories, L.P. | $112.02 | 2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $105.88 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $103.02 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Antares Pharma, INC. | $88.12 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Takeda Pharmaceuticals U.S.A., INC. | $85.26 | 2022-2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $80.01 | 2024-2025 | |
| Pfizer INC. | $77.93 | 2022-2023 | |
| Neurelis, INC. | $76.06 | 2023-2024 | Valtoco |
| Amgen INC. | $48.44 | 2022 | |
| Sumitomo Pharma America, INC. | $39.15 | 2023 | Gemtesa |
| Dexcom, INC. | $34.41 | 2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $30.93 | 2022 | |
| Harmony Biosciences LLC | $26.20 | 2024 | |
| Lundbeck LLC | $21.28 | 2025 | Rexulti |
| Corium, LLC | $20.02 | 2023 | Azstarys |
| Medtronic, INC. | $19.49 | 2025 | Inceptiv |
| Axsome Therapeutics, INC. | $18.01 | 2023 | Auvelity |
| Janssen Pharmaceuticals, INC | $17.87 | 2022 | |
| Baxter Healthcare | $17.82 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.49 | 2025 | Gvoke Hypopen |
| Daiichi Sankyo INC. | $15.09 | 2023 | Injectafer |
| Seqirus USA INC | $13.98 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Ironwood Pharmaceuticals, INC | $12.74 | 2023 | Linzess |
| Merck Sharp & Dohme LLC | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.